A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
- Conditions
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT04036448
- Locations
- 🇰🇷
Local Institution - S10, Jeonju-si, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Local Institution - S06, Seoul, Korea, Republic of
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 424
- Registration Number
- NCT03989414
- Locations
- 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿Local Institution - 802, Brno, Czechia
🇨🇿Local Institution - 801, Ostrava-Poruba, Czechia
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 39
- Registration Number
- NCT03983161
- Locations
- 🇺🇸
University Of Miami Miller School Of Medicine, Miami, Florida, United States
🇺🇸Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center OCRC, Orlando, Florida, United States
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT03983239
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 131
- Registration Number
- NCT03971825
- Locations
- 🇩🇪
Charite Research Organisation GmbH, Berlin, Germany
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT03958864
- Locations
- 🇺🇸
Paraxel International, Glendale, California, United States
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 202
- Registration Number
- NCT03952039
- Locations
- 🇦🇹
Local Institution - 153, Wels, Austria
🇦🇹Local Institution - 155, Linz, Austria
🇦🇹Local Institution - 151, Salzburg, Austria
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile-Hemato-Oncology, Santiago, Metropolitana, Chile
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 195
- Registration Number
- NCT03915769
- Locations
- 🇯🇵
Local Institution - 122, Chikushino, Japan
🇯🇵Local Institution - 119, Ogaki, Japan
🇯🇵Local Institution - 139, Abiko, Japan
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT03906526
- Locations
- 🇺🇸
Local Institution - 103, Sioux Falls, South Dakota, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States